ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01459601
Recruitment Status : Unknown
Verified October 2011 by Haleh Rokni Yazdi, Mashhad University of Medical Sciences.
Recruitment status was:  Not yet recruiting
First Posted : October 25, 2011
Last Update Posted : October 25, 2011
Sponsor:
Information provided by (Responsible Party):
Haleh Rokni Yazdi, Mashhad University of Medical Sciences

Brief Summary:
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Condition or disease Intervention/treatment Phase
Diabetes Type 2 Drug: Cabergoline Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
Study Start Date : January 2012
Estimated Primary Completion Date : February 2012
Estimated Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Sugar
U.S. FDA Resources


Intervention Details:
    Drug: Cabergoline
    0,5mg per week
    Other Name: Dastinex


Primary Outcome Measures :
  1. FBS (fasting blood sugar) [ Time Frame: 30days ]

Secondary Outcome Measures :
  1. HbA1C [ Time Frame: 30days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1C>7

Exclusion Criteria:

  • HbA1C>10
  • Psychiatric disorders

Responsible Party: Haleh Rokni Yazdi, assisstant professor, Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01459601     History of Changes
Other Study ID Numbers: CabergolinDM
First Posted: October 25, 2011    Key Record Dates
Last Update Posted: October 25, 2011
Last Verified: October 2011

Keywords provided by Haleh Rokni Yazdi, Mashhad University of Medical Sciences:
diabetes mellitus
FBS
HbA1C
Cabergoline

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cabergoline
Antineoplastic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs